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ABSTRACT 
To protect the biological activity of an enzyme during the development of formulations is one of the biggest challenges. The tetrameric form of 
L-Asparaginase is used to treat Acute Lymphocytic Leukaemia. It possesses shorter in vivo half–life. Using a modified (water/oil)/water-
emulsion method followed by solvent evaporation L-Asn was successfully encapsulated at the core of Solid Lipid Nanoparticles made of lipid 
glyceryl monostearate. This study elucidated that the preparation of L-Asn loaded SLN develop a colloidal formulation with enhanced activity. 
The in-vitro release proﬁle of the enzyme revealed ﬁrst bursts has been increased. The study of the lyophilised formulation also shows that the 
enzyme holds its biological activity and retains its particle size distribution. Consequently, by using an apt combination of homogenisation 
speed, temperature and additives the storage and biological activity of L-Asn in SLN formulation can be improved. 
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1. INTRODUCTION 
Proteins are known for their delicate molecular 
configuration and its relation to their biological activity 
hence development of a drug delivery system for proteins is 
an all-time big challenge to the pharmaceutical Industry. 
Enzyme L-Asparaginase is used specifically in the treatment 
acute lymphoblastic leukaemia. L-Asparaginase is well 
known for its ability to catalyse the biochemical reaction that 
converts proteinogenic amino acid L-Asparagine and 
produces L-Aspartic Acid and ammonia. This amino acid L-
Asparagine is required in the biosynthesis of glycoproteins 
and other proteins. The ultimate mechanism of action of the 
L-ASN is that when L-Asparagine that cannot be auto 
synthesized by cancer cells unlike normal cells and upon 
degradation in the blood circulation turns to a state of 
malnourishment and ultimately famishing malignant cells. 
Short in vivo circulation is one of the prominent problems of 
L-asparaginase just like other proteins so to meet the desired 
therapeutic levels it turns inevitable to have multiple 
intravenous injections 1. Oscillating L-Asparaginase 
concentration in the blood accompanying variety of side 
effects extending from minor allergic reactions to fatal 
anaphylaxis 2,3. Anaphylactic authors have also proposed the 
administration of the L- asparaginase incorporated in 
liposomes 4–6. Encapsulation protects the protein from its 
proteolysis and can extend the drug release. This 
encapsulation as liposomes of as SLN always comes with a 
biggest challenge of retaining the stability of the protein 
entrapped and it may be due unfavourable micro 
environment which interferes the integrity of the protein 
and affect its biological activity. Encapsulation still at its best 
loses the biological activity but at the worst can produce 
immunogenic or toxic products.  As an alternative carrier for 
the delivery of therapeutic proteins, Solid lipid particulate 
systems have a lot of potential to explore. In this research 
work an optimum particulate carrier system of Solid Lipid 
Nanoparticles with L-ASN was developed through 
optimisation of various parameters. The aim of this research 
was to incorporate hydrophilic proteins using optimum 
particulate system formulation and nanospheres (Gaspar et 
al., 1998). The formulation development process was 
examined to characterise the inﬂuence of optimisation 
parameters in context to the type and concentration their 
excipients used, (lipids and surfactants), mechanical 
parameters like the type of stirrer and speed used and the 
impact of temperature on the size and biological activity of 
the enzyme. SLN formulation of L-Asparaginase protects the 
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enzyme from antigen determinants and increased the 
circulating time in blood confers its sustained release with 
intact biological activity. The biological activity of L-
asparaginase was studied during its formulation 
development, storage, and release. L-Asn loaded SLN was 
prepared using melted lipid glyceryl monostearate, 
surfactants Span 80 and Tween 20 and 10000 rpm stirring 
speed at a constant temperature of 50°C throughout 
produces nanospheres, with 86 % (w/w) recovery and a 
mean diameter of 164 mm and a narrow size distribution.  
2. MATERIALS AND METHODS  
2.1 Materials 
L-Asparaginase was purchased from United Biotech (P) Ltd. 
as a lyophilised powder.  Apart from enzyme other chemicals 
procured from HIMEDIA Laboratories (Mumbai, India) were 
of analytical grade. 
2.2 L-asparaginase-loaded Solid Lipid Nanoparticles 
formulation 
L-Asparaginase encapsulated in Solid Lipid Nanoparticles 
were prepared by adjusting and optimising a double 
emulsion method (w/o)/w followed by solvent evaporation 
7. In this process 1000 ul of l-asparaginase was added in 275 
mg of melted lipid glyceryl monostearate (GMS) solubilised 
in acetone and emulsified by using high speed homogeniser 
(homogeniser: Heidolph Instruments GmbH & CO. KG 
Walpersdorfer, Silent Crusher M, Z664952, Schwabach, 
Germany) at a speed of 10000 rpm at 40°C for 5mins  on a 
thermostat hot plate (magnetic stirrer cum hot plate, 
Heidolph Instruments GmbH & CO. KG Walpersdorfer, Hei-
Tec P/N: 505-30000-00, Schwabach, Germany). This primary 
emulsion was converted to secondary emulsion (w/o)/w by 
adding 20 ml of an aqueous solution containing Tween 20 
(2%) under continuous stirring on the magnetic stirrer for 
one hour at 1000 rpm followed by evaporation of acetone. 
The nanospheres were centrifuged at 4°C, 12000 rpm for 20 
min. It was resuspended in distilled water. The centrifuged 
nanoparticles were filtered through1 µm pore size 
microfilter and stored at -20°C. The particle size and zeta 
potential were studied by laser diffraction particle analyser 
(Delsa™Nano Submicron Particle Size and Zeta Potential, 
Beckman Coulter INC. Brea, CA). 
2.3 Quantiﬁcation of biologically active enzyme in SLN 
L-Asparaginase encapsulated in Solid Lipid Nanoparticles 
was estimated for its biological activity using different 
methods of extraction. Nanospheres were added into PEG 
200, PEG 400 to dissolve lipids and to make the enzyme free. 
In addition to it mechanical methods, organic solvents and 
alkaline solutions were also used to disintegrate and further 
release the biologically active form of the enzyme. The 
enzyme was finally extracted from the suspension at a pH 7.4 
in the phosphate buffer. The disintegrated nanoparticles 
were centrifuged to collect enzyme and multiple extractions 
were done. Total protein content in the suspension was 
determined. Most importantly, the biological activity of 
enzyme in the supernatant was also determined. 45 mg of 
SLN nanoparticles were suspended in 5 ml distilled water 
and sonicated with ultasonicator for 30 min.  
2.4 Determination of the total protein content  
The disintegrated sample was further characterised using 
two different method to estimate the total protein content 
and the biological activity of the enzyme released from SLN 
micro BCA protein-assay was used to estimate the total 
protein content. In this method protein was kept in alkaline 
solution and reduces Cu2+ to produce a complex bicinchonic 
acid–Cu with a characteristic violet colour which was later 
quantified using spectrophotometer at wavelength of 562 
nm. In the protocol, protein sample and reagent in a 
proportion of 1:1 was incubated for 60 min at 60°C in the 
darkness followed by cooling of the reaction mixture to 
normal room temperature for next 30 min and the 
absorption was observed at 562 nm. It was done in triplicate 
and repeated as and when required.  
2.5 Determination of biologically active protein of SLN 
The biological activity of the enzyme released after 
disintegration was measured using an established method of 
Wriston with little modifications 8. L-Asparagine converted 
to L-aspartic acid and ammonia through a biochemical 
reaction catalysed by L-asparaginase. Ammonia thus 
released reacts with Nessler's reagent produces a light 
orangish-yellow coloured complex and its reading was 
estimated using UV spectrophotometer at 425 nm 
wavelength. The reaction mixture assay consisted of 1.7ml of 
0.01 M L-asparagine which was prepared in 0.05 M Tris-HCl 
buffer (pH 7.4), 500 ul of enzyme containing sample was 
incubated at 37°C for 60 min and the reaction was stopped 
by adding 100 μL of 1.5 M Trichloroacetic acid was used to 
abort the reaction. It was followed by centrifugation at 
14000 rpm for 15 min.  0.5 ml of clear supernatant collected 
was added to 7.0 ml reagent grade water. 1ml of Nessler’s 
reagent was added and vortexed. It was further kept for 10 
minutes. OD was measured at 425 nm using UV visible 
spectrophotometer.  It was also done in triplicate and 
repeated as and when required.  
2.6 In vitro release studies 
Nanospheres were resuspended in 0.05 M Tris-buffer pH 7.4. 
PEG 400 (1%) was added followed by Sodium Lauryl 
Sulphate (0.01%). 1.25 ml aliquots of suspension containing 
1.5–3 mg SLN were transferred to microtubes and sealed 
tightly. The samples were placed in shaker incubator at 37°C 
at 70 rpm. From 72 hrs, for every 24hrs the pH of the release 
medium was adjusted by 5N NaOH to 7.0–7.5. 03 samples 
were collected at different time intervals. The sample 
immediately after collection at a specific time interval was 
centrifuged at 8000 rpm for 15 min using refrigerated 
centrifuge machine at temperature of 4°C. The clear 
supernatant was then assayed for the biological activity of 
the enzyme and for the determination of total protein 
content as mentioned earlier.  
3. RESULTS 
3.1 Stability studies of L-Asparaginase in the preparation 
of SLN formulation 
Preparation of Solid Lipid Nanoparticles by modified double 
emulsion method followed by solvent evaporation is a multi-
step process critical for biological activity of enzymes. First, 
during formation of the primary elusion (w/o), the 
hydrophilic enzyme can get denatured at the interface of 
aqueous/organic solvent. It may get adsorbed at this 
interface leads to the unfolding of the protein results in 
partial or total loss of catalytic activity. As mentioned in 
(Table 1).  
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Table 1: Influence of acetone on the biological activity of L-Asparaginase in aqueous solution 
State of Study Enzyme L-Asparaginase (µg/ml) Biological Activity (%) Protein Content (%) 
Without Acetone 118.00 100± 6.1 100.0 ± 0.1 
With Acetone 226.00  91.1 ± 0.2 94.2 ± 1.7 
189.78 80.9 ± 2.6 102.0 ± 5.3 
118.00 72.8 ± 1.6 98.0 ± 2.1 
59.00 65.1 ± 5.1 97.2 ± 4.1 
29.50 56.3 ± 2.1 99.5 ± 2.4 
14.75 44.9 ± 0.7 98.3 ± 2.3 
7.38 18.8 ± 0.8 99.0 ± 4.7 
3.69 9.2 ± 1.7 97.9 ± 3.4 
 
When the aqueous solution of L-Asparaginase emulsified 
with melted glyceryl monostearate lipid dissolved in acetone 
at a volume ratio of 1:2 leads to a considerable decline in 
enzyme activity with dilution of the protein solution. This 
loss of biological activity was strongly dependent on the area 
of interface and the concentration of the enzyme used and 
was found highly comparable, the total quantity of biological 
activity lost found to be constant in all enzyme dilutions. So, 
it was found that the higher enzyme concentrated retains 
more biological activity that the diluted one. The enzyme’s 
biological activity also got affected due to processing 
conditions for getting the desired particulate size like 
temperature and stress generated due to shear forces. 
Unlike the biological activity of the enzyme the protein 
content remains unaffected even at the interface. Although 
loss of biological activity was observed but emulsion was 
found stable as no insoluble aggregated were seen. Although 
reduction of exposure from 30 to 15 s increased the L-
asparaginase activity by 25.7 ± 1.3%, insufﬁcient 
emulsiﬁcation resulted in immediate coalescence of the 
droplets. Thus, ultrasonication for 30 s at the minimum was 
required. In the process of emulsification, a decrease in the 
loss of biological activity of the protein with the increasing 
concentrations of the enzyme in aqueous solution were 
found concurrent (Table 2).  
 
Table 2: Influence of emulsification with acetone by high speed homogenisation on       the activity of L-Asparaginase 
Enzyme L-Asparaginase in Primary 
phase of emulsion (mg/0.5ml) 
Enzyme activity prior 
emulsiﬁcation (U) 
Enzyme activity after 
emulsiﬁcation (U) 
Enzyme activity after 
emulsiﬁcation (%) 
2.126 232.13±0.8 198.34±0.2 85.4 
1.063 149.78±0.4 105.21±1.2 70.2 
5.31.5 76.1±1.6 48.05±2.2 63.1 
0.266 33.50±4.2 15.05±1.2 44.9 
 
3.2 Stability studies of L-Asparaginase in the aqueous 
solution 
The preparation of enzyme loaded SLN formulation L-
Asparaginase as double emulsion requires high speed 
homogenisation, temperature and acetone as organic 
solvent. The stabilising effect of processing parameters 
(homogenisation speed, homogenisation time and 
temperature); additives like acetone and pH on the activity of 
l-asparaginase in aqueous solution was investigated (Table 
3). The protein possesses maximum biological activity at pH 
8.6 although biological activity of L-Asparaginase ranging 
between pH 7.0 to 9.25 9. The enzyme observed to show 
maximum biological activity in 0.05 M Tris Buffer at 8.6. The 
activity got decreased to almost 30 % in tris buffer at pH 8.0 
and further decreased to approx. 70% in phosphate buffer at 
pH 7.4 10. Homogenisation speed was used to make a stable 
emulsion and shear stress to reduce the particle size, but it 
had a great impact on the stability of the activity of the 
enzyme. To attain the desired particle size of nanospheres (˂ 
200nm), 10000 rpm homogenisation speed was used for 
making w/o primary emulsion. It was observed that the 
decrease in homogenisation speed increase the biological 
activity as less speed produces comparatively lesser shear 
stress on the tetrameric structure of the enzyme. The process 
of producing w/o primary emulsion due to higher melting 
point the lipid used glyceryl monostearate was carried out at 
a constant temperature of 30°C. The biological activity of the 
enzyme was completed retained at 30°C but started 
decreasing as the temperature increased and completely lost 
at 47°C. 
Table 3: Influence of pH and additives on the biological 
activity of the enzyme L-Asparaginase 
Study Parameter Enzyme Activity (%) 
Water pH 8.6 95.6 ±1.4 
Water pH 7.4 91.9±8.9 
Water pH 6.6 79.1±0.3 
0.5 M Tris Buffer pH 8.6 74.3±0.2 
0.05 M Tris Buffer pH 8.6 68.1±1.4 
0.05 M Tris Buffer pH 7.4 60.5±5.1 
0.5 % aqueous glycerol 65.9±1.7 
1% aqueous glycerol 46.2±2.8 
10% aqueous glycerol 21.6±1.6 
1% aqueous Pluronic F127 98.3±0.2 
1% aqueous PEG 400 68.0±9.8 
10% aqueous PEG 400 41.8±2.6 
   
3.3 Stability studies of L-Asparaginase in nanoparticles 
L-Asparaginase loaded SLN formulations were prepared and 
studies in the presence of well-established stabilising agents 
PEG 400, Pluronic 127, Glycerol and Tris In practice, the 
average particle size of all the formulations prepared using 
different stabilisers were found to be 318± 8 nm (Table 4). 
All formulations were monodispersed, and huge particles 
lost upon its filtration through microfilter and affect the yield 
in the presence and absence of stabilisers. The encapsulation 
of enzyme was low with PEG 400 based formulation in 
comparison to that of glycerol, Pluronic 127 and Tris buffer. 
The activity of the enzyme incorporated in nanospheres was 
also studied when stabilisers were a component of the inner 
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and outer aqueous phase (Table 5). Tris-buffer denaturated 
the entrapped enzyme give less biological activity followed 
by Pluronic 127. In contrast, formulation prepared with 
stabiliser glycerol and PEG 400, more enzyme activity was 
reported in comparison to the additive-free nanoparticles.
 
Table 4: Characterisation of enzyme L-Asparaginase loaded SLN in the presence of stabilisers 
Inner aqueous phase Median Particle 
Size 
Yield Recovered 
(%) 
Final 
Loading (%) 
Entrapment 
Efficiency (%) 
L-ASN in water 310 51.5±0.3 0.36 76.1 
L-ASN in 0.5 M Tris Buffer pH 8.6 234 36.9±0.6 0.51 73.9 
L-ASN in Glycerol 326 56.34±0.1 0.38 80.6 
L-ASN in 10% PEG 400 360 57.46±0.1 0.16 24.7 
L-ASN in 1 % Pluronic F127 198 39.2±1.2 0.32 62.5 
 
Table 5: Biological activity of L-Asparaginase in the presence and absence of different stabilisers 
Inner core aqueous phase (L-Asparaginase in) Biological activity of L-Asparaginase 
encapsulated in SLN (%) 
Water 16.2±1.4 
1% aqueous Pluronic F127 9.2±1.8 
10% PEG 400 43.5±0.4 
0.5% Glycerol 53.2±7.9 
0.5 M Tris Buffer pH 8.6 Not detected 
 
3.4 In vitro release studies of biologically active L-
Asparaginase protein from SLN formulation prepared 
with stabiliser 
Without any stabiliser and preservative in 60 mM Phosphate 
buffer at pH 7.4, a huge loss of the biological activity in the 
first 24 hrs of in vitro release studies has been already 
reported. PEG 400 (1%) as stabiliser and Sodium Lauryl 
Sulphate (0.01%) as preservative were added in 50 mM Tris-
buffer at pH 7.4 to study the in vitro enzyme release studies. 
The in vitro release studies of the biologically active enzyme 
from Solid Lipid Nanoparticles with comparable size in the 
presence of different stabilisers was also studies and it 
showed that different stabilisers produce their different 
effects on the initial burst (Fig. 1). As the surface 
characteristics of the nanoparticles change with the 
stabilisers that in turn hampers or increase initial first burst. 
In this initial burst study, least loss of SLN was witnessed 
with glycerol followed by PEG 400, Pluronic 127 and Tris 
buffer respectively. Hence the biological activity was also 
highest in nanoparticles with glycerol and lowest in Tris 
buffer. 
3.5 Stability studies of lyophilisation on the particle size 
and biological activity of   L-Asparaginase nanoparticles 
Lyophilisation of enzyme loaded nanoparticles resulted in 
formation of aggregates of size ranging in the micrometres 
that was also difficult to dissociate by ultrasonication. The 
effect of three lyoprotectans viz Tris buffer, glycerol and 
Pluronic F127 were studied on the enzyme loaded 
nanoparticles. Glycerol increases the particle size to 3 times 
with a considerable loss of biological activity. Tris buffer also 
increases the particle size during lyophilisation, but very 
little enzyme activity got lost. Pluronic F127 witnessed to be 
the best among the three in retaining the size and biological 
activity of L-Asparaginase.  
 
 
Figure 1: In vitro release study of L-ASN loaded SLN with different stabilisers  
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Table 6: Influence of stabilisers on particle size and enzyme activity of L-ASN loaded SLN during lyophilisation  
L-ASN loaded SLN Stabiliser Used Particle Size (nm) Biological activity (%) 
After Preparation  - 164.3  
Before Lyophilisation  - 198.1 34.6 
After Lyophilisation  No stabiliser 15479 11.2 
0.5 % Glycerol 6378 1.5 
0.05 M Tris Buffer 8392 9.7 
1% Pluronic F 127 307 24.3 
 
4 DISCUSSIONS 
The biological activity and structural stability of an enzyme 
is of utmost importance for any pharmaceutical formulation. 
To overcome all the possible sources of enzyme 
denaturation were identified in the study.  A loss of 
biological activity of L-asparaginase was observed high at 
low protein concentrations at aqueous organic solvent 
interface. The method of double emulsification requires high 
speed which also affects the biological activity of the protein 
by generating shear stress on the enzyme in aqueous phase. 
At high protein concentrations these effects got 
comparatively reduced 11. The formulation was further 
characterised after the involvement of stabilisers. Pluronic 
F127 was found to be the most successful stabilising agent in 
the stability studies performed in the aqueous solution of the 
enzyme 12. The maximum biological activity of the enzyme 
was at pH 8.6 although it ranges fairly between pH 7.0 - 9.0. 
PEG 400 was used as in the release medium and gives good 
first burst but the enzyme lost its activity in the first 72 hrs 
and the enzyme found instable in PEG 400. Initially glycerol 
observed to be supportive in enzyme’s stability, but it is not 
found suitable in maintaining particle size distribution and 
enzyme activity during lyophilisation.  
5 CONCLUSIONS 
A combination of stabilisers may improve stability of 
enzyme l-asparaginase in SLN e.g. the use of PEG 400 or 
glycerol to maintain enzyme activity during SLN preparation 
Pluronic F127 as a potent lyoprotectant. To retain the 
complete biological activity with the use of stabilisers is 
highly desirable.  
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